Abbott’s Libre Duo. We found a copy of the user manual…
We found an early copy of the Libre Duo User Manual (dated from 2025) so we thought we’d dig into it and see what it said.
Blog Posts
Did a change of glucagon derail the Inreda artificial pancreas trial?
Inreda’s recent year long study on their dual hormone AID system didn’t produce the results anyone wanted. Here we dig into that further.
Whose data is it anyway?
Following Dexcom’s recent “Terms Update Debacle”, Diabettech took a a deep dive into what happened, what it means, and whether some of the content of recent updates to terms run counter to the overarching rules about personal health data in various jurisdictions.
Data every minute, one AID and a predictable outcome: what happens when you run an oref based loop on minute-by-minute data on body
Following the side by side evaluation of the various algorithms on 1 minute sensors with different decision cadence, this is what happened when I took it in-vivo and allowed those different cadences to run with a proper feedback loop.
Patch pump purgatory: the mechanics of a patch pump on skin
As we saw more an more manufacturers attempting to bring patch pumps to the market, I felt it was time to look at some of the mechanical design challenges that they face, and how those affect their ability to deliver treatment.
Losing Lyumjev: how the system failed patients
As various presentations of Lyumjev are withdrawn across Europe, we take a deep dive into what lies behind the commercial reasons that Lilly has stated.
Almost AGI? The latest AI models still haven’t shown they can beat humans at carb counting…
This is a follow-up to I asked AI to count my carbs 27,000 times. It couldn’t give me the same answer twice. The full preprint […]
Zucara’s ZT-01: what could taking the brake off glucagon do?
ZT-01 aims to restore glucagon counterregulation during hypoglycaemia. But type 1 diabetes already produces glucagon at the wrong time — and Zucara’s own human data show SSTR2 blockade raises glucagon, glucose and insulin requirements during euglycaemia. What will the trials tell us about its longer term effects?
More Bolus, Less Basal: What Happens When oref Loops Run More Frequently
When you give an oref based hybrid closed loop minute by minute data, what happens to it’s insulin delivery choices? This is where we find out.
Your CGM Knows You Ate. It Can’t Tell What You Ate.
How much of a meal signal is there in glucose data, and what can you do with it? This article describes a deep dive into a large dataset and tells us what it finds.